CVS Health goes into the biosimilar market with new subsidiary
CVS Health announced Wednesday that it launched a business that will work with drugmakers to commercialize and manufacture biosimilars in the US, starting with a Humira biosimilar developed by Sandoz.
Sandoz has said it plans to launch Hyrimoz in September, and now the biosimilar will also be made available in the first quarter of 2024 under the private label for Cordavis, the new CVS subsidiary. CVS said it expects the biosimilar to cost 80% less than the current list price for Humira, AbbVie’s blockbuster therapy that lost patent exclusivity this year. GoodRx lists the price for two pens of Humira between $6,000 and $7,000 at various retailers.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.